Articles

cath lab cardiovascular surgery clinical trial/study scai heart attack

The Society for Cardiovascular Angiography and Interventions (SCAI) assembled  a panel that has proposed new criteria for identifying patients who experience a heart attack after coronary...

heart disease, breast cancer, HDL

High levels of high-density lipoprotein (HDL) have been linked to increased breast cancer risks and enhanced cancer aggressiveness in animal ...

Cath Lab pharmaceuticals clinical trial study CNIC spain icahn heart attack

Early treatment of heart attack patients with an inexpensive beta-blocker drug called metoprolol, while in transit to the hospital, can significantly reduce damage to the heart during a...

CTA, CCTA, CT angiography

A large number of emergency room visits are for chest pain evaluation, and many hospitals are adopting CT angiography as a primary test to quickly rule-out coronary disease.

Medicare Expenses Growth Heart Attack Patients 1998 2008

Medicare expenses for patients with acute myocardial infarction (AMI, heart attack) increased substantially between 1998 and 2008, with much of the increase coming in expenses 31 days or more...

Icahn School of Medicine at Mount Sinai PARIS Study Antiplatelet Therapy PCI

Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC...

Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non–ST-segment elevation...

Transcatheter aortic valve implantation (TAVI) is feasible in patients with bicuspid aortic valve (BV), according to research presented at European Society of Cardiology (ESC) Congress 2013 by Dr...

Researchers announced this week that an attempt to expand cardiac resynchronization therapy (CRT) to include more patients with heart failure has failed and an international clinical trial ended...

September 3, 2013 — St. Jude Medical Inc. announced the CE mark approval of its next-generation EnligHTN renal denervation system for treating patients with drug-resistant, uncontrolled...